Oncotelic And TechForce Robotics Partner To Commercialise AI-Driven GMP Robotics Platform For Pharma Manufacturing

Oncotelic Therapeutics, Inc. has announced a strategic partnership with TechForce Robotics, Inc. to accelerate the commercialisation of a GMP-compliant robotics platform powered by its proprietary PDAOAI technology. This collaboration marks a significant step toward translating years of research into a deployable solution to enhance pharmaceutical manufacturing and related operations.

The jointly developed platform integrates Oncotelic’s AI-driven PDAOAI capabilities with TechForce’s robotics hardware and manufacturing expertise. Designed for use in GMP-regulated environments, the system automates material handling, enables real-time monitoring, and strengthens compliance workflows, helping streamline complex pharmaceutical processes.

"This commercialisation represents a significant step forward in bridging PDAOAI and automation within regulated pharmaceutical environments," said Dr. Vuong Trieu, chairman and Chief Executive Officer of Oncotelic. "After years of development, we are now positioned to advance our transformative solution toward commercialisation that can enhance compliance, reduce operational risk, and improve efficiency across the industry."

A key focus of the platform is improving operational efficiency while maintaining strict regulatory standards. By reducing manual intervention, the system aims to lower contamination risks and ensure greater process consistency. It also incorporates intelligent automation features such as deviation detection, time-stamped documentation, and continuous data-driven optimization, supporting audit readiness and validation requirements like IQ, OQ, and PQ.

Ried Floco, president of TechForce Robotics, added, "Our collaboration with Oncotelic demonstrates the power of combining advanced AI with purpose-built robotics systems. With our manufacturing and deployment capabilities, we are now working toward scaling this solution for real-world applications."

The partnership is supported by a joint development, manufacturing, and licensing agreement that creates a structured pathway for scaling production and commercial deployment. With its combination of AI and robotics, the platform is positioned to support future-ready manufacturing environments, addressing both efficiency and compliance challenges across the pharmaceutical industry.